HCPCS Level II · Drugs administered other than oral method
J9250Methotrexate sodium, 5 mg
Terminated 03/31/2024
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9250
J9250 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing methotrexate sodium, 5 mg.
It was added to HCPCS effective 01/01/1994, and its current record took effect 04/01/2024.
It was terminated on 03/31/2024 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Methotrexate sodium inj
- Date added
- 01/01/1994
- Action effective
- 04/01/2024
- Termination date
- 03/31/2024
- BETOS
- O1D
Related J92xx codes
- J9200Injection, floxuridine, 500 mg
- J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202Goserelin acetate implant, per 3.6 mg
- J9203Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204Injection, mogamulizumab-kpkc, 1 mg
- J9205Injection, irinotecan liposome, 1 mg
- J9206Injection, irinotecan, 20 mg
- J9207Injection, ixabepilone, 1 mg
- J9208Injection, ifosfamide, 1 gram
- J9209Injection, mesna, 200 mg
- J9210Injection, emapalumab-lzsg, 1 mg
- J9211Injection, idarubicin hydrochloride, 5 mg
Common questions about J9250
Is HCPCS J9250 still valid?
- No. J9250 was terminated on 03/31/2024.
Does Medicare cover J9250?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.